Trials / Completed
CompletedNCT00661375
BAY43-9006 Phase II Study for Renal Cell Carcinoma
Phase II Study of BAY 43-9006 in Japanese Patients With Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 131 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate efficacy, safety, and pharmacokinetics of BAY 43-9006 in patients with unresectable and/or metastatic renal cell cancer (RCC) who have failed at least one cytokine containing regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nexavar (Sorafenib, BAY43-9006) | BAY 43-9006 400mg b.i.d. Treatment will continue until progression of underlying disease, unacceptable toxicity whose causal relationship to the study drug cannot be ruled out and which requires discontinuation of the drug, or consent withdrawal. |
Timeline
- Start date
- 2004-11-01
- Primary completion
- 2006-03-01
- Completion
- 2006-03-01
- First posted
- 2008-04-18
- Last updated
- 2014-12-25
Locations
51 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00661375. Inclusion in this directory is not an endorsement.